OneBullion_Logo.Primary.jpg
Imperial Ginseng enters into Merger Agreement to acquire One Bullion Ltd.
September 13, 2024 08:00 ET | Imperial Ginseng Products Ltd.
VANCOUVER, BRITISH COLUMBIA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Imperial Ginseng Products Ltd. (TSXV: IGP) (the “Company”) is pleased to announce that it has entered into a definitive merger...
ApogeeLogo.png
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
September 12, 2024 07:00 ET | Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
ApogeeLogo.png
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
September 09, 2024 07:00 ET | Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
The Brainy Insights.png
Flow Cytometry Market Expected to Achieve USD 10.16 Billion in Revenues By 2033, Driven By a 8.13% CAGR
September 05, 2024 08:30 ET | The Brainy Insights
Newark, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The flow cytometry market is experiencing significant growth, driven by advancements in technology, increasing applications in clinical diagnostics, and a...
ApogeeLogo.png
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 19, 2024 07:00 ET | Apogee Therapeutics, LLC
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024 16:05 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
ApogeeLogo.png
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 12, 2024 06:30 ET | Apogee Therapeutics, LLC
Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q...
sphericalinsightsoptionblue.png
Global Agricultural Lighting Market Size To Worth USD 35.83 Billion By 2033 | CAGR Of 12.1%
August 02, 2024 12:00 ET | SPHERICAL INSIGHTS LLP
New York, United States, Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Global Agricultural Lighting Market Size is to Grow from USD 11.4 Billion in 2023 to USD 35.83 Billion by 2033, at a Compound Annual...
The Brainy Insights.png
Aluminium Curtain Wall Market Size Projections Exhibit a CAGR of 8%, Likely to Attain a Value of USD 92.83 Billion by 2033
July 31, 2024 20:00 ET | The Brainy Insights
Newark, July 31, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 43 billion in 2023 global aluminium curtain wall market will reach USD 92.83 billion in 2033. In architecture and...
NewAmsterdam Logo_full color_Final.png
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024 08:00 ET | NewAmsterdam Pharma N.V.
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...